<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01711021</url>
  </required_header>
  <id_info>
    <org_study_id>N25-006</org_study_id>
    <nct_id>NCT01711021</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety &amp; Efficacy of d-Amphetamine Transdermal System Compared to Placebo in Children &amp; Adolescents With ADHD</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety and efficacy of d-Amphetamine Transdermal System for the
      treatment of Attention Deficit Hyperactivity Disorder in children and adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a four-week screening period, a 3-day wash-out period (if
      applicable), a five-week open-label, step-wise dose optimization period and two-week double
      blind randomized crossover treatment period with weekly classroom assessments and a safety
      follow-up by telephone 7 - 10 days after last dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in total SKAMP Scores</measure>
    <time_frame>Measured weekly during a two-week double-blind treatment period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>d-Amphetamine Transdermal System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>d-Amphetamine Transdermal System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-Amphetamine Transdermal System</intervention_name>
    <description>Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.</description>
    <arm_group_label>d-Amphetamine Transdermal System</arm_group_label>
    <other_name>d-Amphetamine</other_name>
    <other_name>Amphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.</description>
    <arm_group_label>Placebo patch</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Sham treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: Male or female;

          -  Age: Between 6 &amp;17 years of age, inclusive;

          -  Race: All eligible;

          -  Females of child-bearing potential must agree to practice a clinically accepted method
             of contraception during the study &amp; for at least one month prior to study dosing &amp; one
             month following completion of the study. Acceptable contraceptive methods include
             abstinence, oral contraception, surgical sterilization (bilateral tubal ligation,
             bilateral oophorectomy or hysterectomy), intrauterine device, or diaphragm in addition
             to spermicidal foam &amp; condom on male partner, or systemic contraception [e.g. Norplant
             System];

          -  Must meet Diagnostic &amp; Statistical Manual of Mental Disorders, 4th edition - Text
             Revision criteria for a primary diagnosis of ADHD combined, predominately hyperactive
             impulsive type, or predominately inattentive type;

          -  The screening &amp; baseline visit ADHD-RS-IV total score must be 90% or greater relative
             to the general population of children by age &amp; gender;

          -  Must be able to wear a patch for 9 hours. Parent or caregiver must be present to apply
             &amp; remove the patches &amp; maintain the used &amp; unused patches in a secure controlled area
             of the home;

          -  Must be functioning at an age appropriate level intellectually as determined by an
             intelligence quotient of ≥80 on the Wechsler Abbreviated Scale of Intelligence II™,
             vocabulary &amp; matrix reasoning components;

          -  Must have the ability to complete PERMP assessment;

          -  Have parental consent &amp; written or verbal assent from the subject;

          -  Subject &amp; parent(s)/caregiver are willing &amp; able to comply with all the protocol
             requirements &amp; parent(s) or caregiver must be able to provide transportation for the
             subject to &amp; from the analog classroom sessions.

        Exclusion Criteria:

          -  Has blood pressure &amp; pulse outside the 95th percentile for age &amp; gender;

          -  Is a known non-responder to amphetamine treatment;

          -  Has a documented allergy, intolerance, or hypersensitivity to amphetamine;

          -  Is currently taking an ADHD medication that is providing symptom control with no
             residual impairment at home or school &amp; has acceptable tolerability &amp; adherence;

          -  Has a recent history (within the past 6 months) of suspected substance abuse or
             dependence disorder (including nicotine);

          -  Has a history of seizures during the last 2 years (exclusive of infantile febrile
             seizures), a tic disorder (exclusive of transient tic disorder), a current diagnosis
             and/or a family history of Tourette's Disorder. Mild medication-induced tics are not
             exclusionary;

          -  Has any psychiatric disorder that could interfere with study participation or the
             safety of the subject or other participants, such as conduct disorder or oppositional
             defiant disorder with a history of prominent aggressive outbursts. Children meeting CD
             or ODD but without prominent aggression will be allowed to enroll at the discretion of
             the investigator;

          -  Has Autism or Asperger's Disorder;

          -  Has a family history (first degree relatives) of sudden cardiac death;

          -  Has current controlled (requiring medication) or uncontrolled comorbid psychiatric
             conditions such as post traumatic stress disorder, psychosis, bipolar illness, severe
             obsessive compulsive disorder, severe depressive or severe anxiety disorder,
             considered a suicide risk, has previously attempted suicide, has prior history of or
             is currently demonstrating suicidal ideation;

          -  Has a history of abnormal thyroid function;

          -  Has BMI for age greater than 95th percentile per CDC BMI-for-gender specific charts;

          -  Has a known history of symptomatic cardiovascular disease, advance arteriosclerosis,
             structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities,
             coronary artery disease, or other serious cardiac problems that may place them at
             increased vulnerability to the sympathomimetic effects of a stimulant drug;

          -  Has any skin abnormality present at the potential application site that is likely to
             be aggravated by the study drug (i.e., infection, rash, atrophy, excessive fragility
             or dryness, any cut or abrasion, or tattoo);

          -  Has a history of hypersensitivity, allergy to topical medication, preparation, or
             adhesive dressings;

          -  Has concurrent chronic or significant acute illnesses (such as severe allergic
             rhinitis or an infectious process requiring antibiotics, unless expected to resolve or
             has resolved by Day 0) disability or any unstable medical condition that in the
             investigator's opinion would lead to difficulty complying with the protocol
             requirements;

          -  Has used any investigational drug within 30 days of the screening visit;

          -  Has a history of physical, sexual, or emotional abuse in the last year;

          -  Has a medical history of Hepatitis A, B,C or HIV;

          -  Has positive urine drug screen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Waxmonsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Not Affiliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Children and Families</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2012</study_first_submitted>
  <study_first_submitted_qc>October 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <disposition_first_submitted>April 1, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 1, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 30, 2014</disposition_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

